Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz, Jean‐Jacques Kiladjian
Leukemia (2020) Vol. 35, Iss. 1, pp. 1-17
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 247
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 246
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 198
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 195
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 191
JAK: Not Just Another Kinase
Ruchi Agashe, Scott M. Lippman, Razelle Kurzrock
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 12, pp. 1757-1764
Open Access | Times Cited: 70
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 32, pp. 4993-5004
Open Access | Times Cited: 55
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 54
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition
Yiming Luo, Madison Alexander, Massimo Gadina, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 911-925
Open Access | Times Cited: 86
Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhi Zhu, A. J. Robert McGray, Weijian Jiang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 57
Tandem construction of biological relevant aliphatic 5-membered N-heterocycles
Daniel Łowicki, Piotr Przybylski
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114303-114303
Closed Access | Times Cited: 42
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
John Mascarenhas
Expert Review of Hematology (2022) Vol. 15, Iss. 8, pp. 671-684
Closed Access | Times Cited: 42
STAT5b: A master regulator of key biological pathways
M.R. Smith, Lisa Forbes Satter, Alexander Vargas‐Hernández
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 32
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 25
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials
Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, et al.
Blood Advances (2023) Vol. 7, Iss. 14, pp. 3582-3591
Open Access | Times Cited: 25
The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 12
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
Stephen T. Oh, Srđan Verstovšek, Vikas Gupta, et al.
eJHaem (2024) Vol. 5, Iss. 1, pp. 105-116
Open Access | Times Cited: 11
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Sahil Hussain, Mohd Mursal, Garima Verma, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176484-176484
Closed Access | Times Cited: 10
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data
Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
Chunjian Liu, James C. Lin, Charles M. Langevine, et al.
Journal of Medicinal Chemistry (2020) Vol. 64, Iss. 1, pp. 677-694
Closed Access | Times Cited: 56
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 12, pp. 2166-2178
Open Access | Times Cited: 51
Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells
Scott J. Sauer, Damon R. Reed, Michael A. Ihnat, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 46
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Elvira Favoino, Marcella Prete, Giacomo Catacchio, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 3, pp. 102750-102750
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top